Arrowhead Pharmaceuticals (ARWR) Peer Comparison

$58.02

$-0.34 (-0.58%)

As on 23-Oct-2026 16:00EDT

Market cap

$8,196 Mln

Revenue (TTM)

$670 Mln

P/E Ratio

--

P/B Ratio

20.6

Div. Yield

0 %

Edit

	Arrowhead Pharmaceuticals (ARWR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	8,196	18,719	15,989	16,015	14,259
Revenue ($ Mln)	670	2,838	2,436	1,054	1,664
Net Profit ($ Mln)	-319.95	517.83	860.62	755.85	413.60
Net Margin (%)	-47.79	18.24	35.33	71.69	24.86
RoE (%)	-71.14	87.53	42.98	--	430.03
Price to Earnings	--	37.16	20.36	18.65	36.73
Price-To-Book	20.55	39.67	7.82	9.82	25.20

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Arrowhead Pharmaceuticals (ARWR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Operating Revenue	669.50	2,838.39	2,435.92	1,054.37	1,663.74
Cost of Revenue	19.14	2,011.22	85.67	103.47	292.42
Gross Profit	829.45	760.62	2,236.43	588.53	1,167.84
Operating Expenses	895.93	220.03	1,378.74	841.45	440.53
Operating Profit (EBIT)	-226.44	607.14	971.51	109.45	930.79
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-252.08	626.99	1,035.47	101.11	583.34
Provision for Tax	20.05	109.17	174.84	-654.74	169.74
Profit after Tax (Net Income)	-319.95	517.83	860.62	755.85	413.60
Minority Interest	-47.83	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Arrowhead Pharmaceuticals (ARWR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Shareholder's Funds	465.53	584.94	1,843.76	1,435.90	143.54
Minority Interest	-47.83	0.00	0.00	0.00	0.00
Non-Current Liabilities	1,362.63	221.56	288.55	384.48	2,089.43
Current Liabilities	283.35	1,496.10	361.93	464.70	344.44
Total Liabilities	1,385.30	1,975.47	2,844.42	1,302.02	2,525.32

Assets ($ Mln)

	Arrowhead Pharmaceuticals (ARWR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Non-Current Assets	440.60	1,057.60	1,243.41	895.24	1,644.38
Current Assets	1,671.41	1,245.00	1,250.82	1,389.84	933.02
Total Assets	1,385.30	1,975.47	2,844.42	1,302.02	2,525.32
Total Debt*	864.07	146.04	165.93	449.89	2,146.65
Net Current Assets	1,388.07	0.00	888.90	925.52	588.59

Cashflow ($ Mln)

	Arrowhead Pharmaceuticals (ARWR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Cash From Operating Activities	179.55	713.22	884.27	51.77	651.56
Cash Flow from Investing Activities	-129.29	-31.14	350.44	-8.15	-545.81
Cash from Financing Activities	74.01	-860.39	-969.59	34.89	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Arrowhead Pharmaceuticals (ARWR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
ROCE (%)	-0.17	57.43	32.82	-30.01	15.61
ROE (%)	-71.14	87.53	42.98	163.18	430.03
ROA (%)	-16.12	15.73	29.32	31.68	16.19
EBIT Margin (%)	-23.82	21.70	41.82	5.73	36.28
Net Margin (%)	-47.79	18.24	35.33	71.69	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Arrowhead Pharmaceuticals (ARWR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Revenue Growth (%)	12.22	20.35	9.23	114.85	41.15
EBIT Growth (%)	-112.42	18.61	29.37	136.39	-14.99
Net Profit Growth (%)	-115.58	19.59	42.89	378.76	-25.78
EPS Growth (%)	-73.87	28.06	50.42	353.27	-23.48
Book Value Growth (%)	-13.57	108.60	-0.70	816.12	-55.81

Valuation Ratios

	Arrowhead Pharmaceuticals (ARWR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Price / Earnings	-2,869.63	36.06	15.79	-59.76	24.99
Price / Book Value	20.55	39.67	7.82	9.82	25.20
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-57.18	28.53	14.43	208.25	22.63
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Arrowhead Pharmaceuticals (ARWR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Debt to Equity	1.77	0.00	0.00	0.27	13.50
Short term debt to equity ratio	0.09	0.00	0.00	0.05	1.46
Current Ratio	5.90	0.83	3.46	2.99	2.71
Quick Ratio	5.90	0.83	3.38	2.32	2.31
Interest Coverage	-1.72	--	--	1.62	29.73

Operating Efficiency Ratios

	Arrowhead Pharmaceuticals (ARWR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Debtors to sales (%)	1.28	15.77	13.74	21.25	27.40
Asset Turnover	0.34	0.86	0.83	0.44	0.65
Receivable days	1.50	50.42	43.48	85.52	98.04
Inventory Days	--	--	96.17	1,056.70	254.12
Payable days	221.81	6.26	147.97	331.01	24.86
Cash Conversion Cycle	--	--	-8.32	811.21	327.29

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly